AIM ImmunoTech Inc (NYSE:AIM) CEO Thomas K. Equels joined Proactive's Stephen Gunnion to share an overview of the company's Pancreatic Cancer Program with Ampligen.
That follows the release of promising follow-on data from its previously published single-center named patient program evaluating its flagship drug candidate as maintenance therapy for pancreatic cancer.
Equels also outlined the next steps for the program.